Please click on the names below for more details on each confirmed speaker:

University of Pittsburgh

I am a cellular immunologist with a research focus on dissecting the role of cytokine signaling in the immunity against renal infections and pathogenesis of autoinflammatory kidney diseases. Building upon my prior work in kidney inflammatory conditions, my research program at University of Pittsburgh addresses a major problem in the field of cytokine Interleukin-17 (IL-17) in renal damage during infection and autoimmunity. The kidney is an organ particularly susceptible to damage caused by infections and autoinflammatory conditions. Even so, renal immunology remains remarkably understudied by immunologists. I have positioned myself to take advantage of this important knowledge gap. Using mouse models and human bio-specimens, we are deeply involved in understanding the mechanisms of kidney tissue damage in infections and autoimmune conditions. Recently, we also showed the mechanisms of immune dysfunction in patients with kidney disease, which leads to increased susceptibility of infection in these patients. Thus, my research embodies the features of a basic scientist with scientific contributions spanning from very basic work in cell/animal models to more clinical work in humans.

Trinity College Dublin

Andrew Bowie is Professor of Innate Immunology at Trinity College Dublin (TCD). He obtained his PhD in Biochemistry from Trinity College Dublin in 1997. After postdoctoral training with Prof Luke O’Neill, he was appointed as a lecturer UCD, before returning to TCD in 2001 to establish the first Immunology undergraduate degree in Ireland. In 2008 he was elected a Fellow of TCD, and in 2014 a member of the Royal Irish Academy. In 2017 he was awarded the Irish Society for Immunology Public Lecture Medal for his outstanding contribution to Irish Immunology. His research focuses on innate immune sensing and signalling mechanisms of pathogens, especially viruses.

University of Oxford

Chris obtained a degree in Biochemistry from the University of Oxford (1985) with subsequent undergraduate training in Medicine (MBBS) at the Royal Free Hospital, London (1990). His postgraduate medical training was in General Medicine and Rheumatology at the Hammersmith Hospital, London and John Radcliffe Hospital, Oxford. He obtained a DPhil arising from a Wellcome Trust Clinical Training Fellowship at the Institute Molecular Medicine, Oxford in 1996.
Funded by a Wellcome Trust Clinician Scientist Fellowship, he joined the Department of Rheumatology in Birmingham later that year. In 2001 he was awarded an MRC Senior Clinical Fellowship and in 2002 became Arthritis Research UK Professor of Rheumatology
In May 2017 he took up a new joint academic post between the Universities of Birmingham and Oxford as Director of Clinical Research at the Kennedy Institute of Rheumatology Oxford and Director of NIHR Infrastructure in Birmingham for Birmingham Health Partners to Direct the Arthritis Therapy Acceleration Programme (A-TAP)

University of Edinburgh

Yanick Crow is a clinical scientist (MD-PhD) and Fellow of the Academy of Medical Sciences, working at the MRC Institute of Genetics and Molecular Medicine, Edinburgh, UK and the Institut Imagine, Paris, France. He has an interest in monogenic disorders associated with an up-regulation of type I interferons – a set of inborn errors of immunity resulting from abnormal sensing, inappropriate stimulation, or defective negative regulation of the type I interferon system. Understanding these so-called type I interferonopathies has the potential to provide insights into immunological homeostasis, mechanisms of self / non-self discrimination and viral immunity.

King’s College London

Franziska Denk is a Senior Lecturer at King’s College London, where she works on neuroimmune interactions and epigenetic mechanisms in the context of chronic pain. Her lab uses transgenic models and high-throughput molecular analyses, such as RNA-seq, on sorted cell populations (, @denk_lab).
Franziska studied Experimental Psychology at the University of Oxford and completed her DPhil there in 2009. She started her own research group in 2017 with the help of an MRC New Investigator Research Grant. Since then, she has also received funding from the European Union (IMI2), industry and several charities.
Franziska is passionate about data sharing (Denk, Nature, 2017) and interdisciplinary research in an open, positive research culture. She is co-Director of the Wellcome Trust funded PhD Training Scheme in Neuro-Immune Interactions in Health and Disease (

Trinity College Dublin

Padraic Fallon is Professor of Translational Immunology, School of Medicine, Trinity College Dublin, Ireland. Research involves the use of animal models, including mutant and transgenic strains, advances fundamental understanding of infection immunobiology and inflammatory disease processes. Translational mechanistic studies address innate and adaptive cellular responses in patient cohorts with inflammatory or infectious diseases.

University of Melbourne

John Hamilton has made significant molecular and translational contributions to the field of inflammation. He has shown how colony-stimulating factors (CSFs) control macrophage lineage numbers and function in inflammation, mainly in the contexts of arthritic disease and inflammation-associated pain. He discovered the role of CSFs in inflammation, pioneered cell signalling studies for the CSFs, and progressed the biology of the CSFs to encourage and facilitate several successful international clinical trials with antagonists to the CSFs, for example, in arthritis and cancer.

Cardiff University

Ian Humphreys is a Wellcome Trust Senior Research Fellow, Professor of Viral Pathogenesis and Director of the Systems Immunity University Research Institute at Cardiff University, UK. The laboratory studies mechanisms that regulate antiviral immune responses and seeks to understand how these processes can restrict viral pathogenesis but also, in certain contexts, facilitate virus persistence and dissemination.

University of Pennsylvania

Dr. Hunter’s laboratory focuses on the events that lead to the development of protective immunity as well as to limit T cell mediated pathology during parasitic infections and the role of cytokines in these processes. We are able to utilize different combinations of transgenic parasites to study how cytokines such as IFN-gamma, IL-2, IL-10, IL-12, IL-18 and IL-27 affect resistance to infection. Dr. Hunter obtained his Ph.D. from the University of Glasgow and is a Professor at the University of Pennsylvania and is the President elect of the ICIS.

Hudson Institute of Medical Research

Professor Brendan Jenkins is Deputy Director of the Centre for Innate Immunity and Infectious Diseases at the Hudson Institute of Medical Research, Australia. His research interest is to define the roles that innate immune regulators, namely pattern recognition receptors and IL-6 family cytokines, play in the pathogenesis of inflammation-associated cancers, including those of the stomach, pancreas and lung. His research programs incorporate long standing collaborations with basic scientific researchers and clinicians both nationwide and overseas, with a view to translate his preclinical findings into the clinic.

University of Bristol
Dr Gareth Jones is a Senior Lecturer in Immunology at the School of Cellular and Molecular Medicine, University of Bristol, UK. His research investigates mechanisms by which IL-6 family cytokines regulate tissue inflammation and damage, with an interest in the negative control of inflammation to restore tissue homeostasis. This has recently been applied to understanding the development and maintenance of ectopic lymphoid-like structures (also called tertiary lymphoid structures) in autoimmunity and cancer. Through collaboration with basic scientists, clinicians and industry, his research spans fundamental and early clinical studies with a view to clinical translation.

St. Jude Children’s Research Hospital

Thirumala-Devi Kanneganti is a Member and Vice Chair of the Immunology Department at St. Jude Children’s Research Hospital, and she is the Rose Marie Thomas Endowed Chair. She is a founding member of the inflammasome field, and her lab continues to make critical contributions to this research discipline. She also identified master regulators of inflammasome activation and the cell death pathways pyroptosis, apoptosis, and necroptosis, leading her to pioneer the concept of PANoptosis and describe its implications in health and disease.

Medical University Innsbruck, Institute of Physiology

Michaela Kress is a physician scientist and full professor at the Department of Physiology and Biomedical Physics Medical University of Innsbruck in Austria. She served as President of the Austrian Neuroscience Association, member of the Scientific Program Committee of several congresses of the international (IASP) and European (EFIC) pain societies. She coordinated the ncRNAPain research consortium funded by the European Commission. She teaches medical students and supervises PhD students in MSCA- and FWF funded programs. Her research focus is on neuroimmune interactions in the nervous system and their hub regulators in the pain pathway. These are explored by integrating multiple methodological approaches ranging from behavior phenotyping to expression analysis and electrophysiological recordings from peripheral nerve and from neuronal networks in the brain. In particular, non-coding RNAs, the proinflammatory cytokine interleukin-6 and its signal transducer Il-6/gp130 are explored and novel models for pain disorders developed with a recent focus on human model systems.

FAU European Grant Gerhard Krönke Life sience 9. Dezember 2014

University of Erlangen

After graduating from the Medical University of Vienna in 2002, Gerhard Krönke worked as postdoctoral researcher at the Medical University of Vienna (2002-2004) and the University of Virginia, Charlottesville (2004-2006). From 2006-2015 he conducted his clinical training in Internal Medicine and subsequently in Rheumatology at the University Hospital Erlangen, where he is currently working as Senior Physician at the Department of Internal Medicine 3 since 2012. In 2016, he was appointed Professor of Translational Immunology at the University of Erlangen-Nürnberg. His research focuses on cellular, molecular and metabolic pathways involved in the maintenance and break of immunological self-tolerance as well as the onset and resolution of inflammation. In particular, he is trying to understand the mechanisms and events leading to the development of inflammatory autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematodes and to develop novel strategies for their diagnosis and treatment. In 2014 he received an ERC Starting grant and is currently acting as the spokesperson of the DFG research unit FOR2886 “PANDORA” (Pathways triggering AutoimmuNity and Defining Onset of early Rheumatoid Arthritis).

Brigham and Women’s Hospital/Harvard Medical School

Dr. Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, an Institute Member of the Broad Institute, a collaborator in the Klarman Cell Observatory project that focuses on T cell differentiation, and Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital.

His major research interests include autoimmune diseases, particularly the role of co-stimulation, the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, and cell surface molecules and regulatory factors that regulate induction of T cell tolerance and dysfunction.

University of Glasgow

Professor Iain McInnes is Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow.

A global leader in the field of arthritis research, over two decades, Professor McInnes has led numerous clinical trials and pathogenesis investigation programmes in inflammatory arthritis at an international level. His work has focused on the biology of inflammatory cytokines in arthritis and extended to other inflammatory diseases. More recently, he has worked on the mechanisms of co-morbidities in chronic diseases. He has also pioneered the area of precision medicine in inflammatory arthritis.

For the last five years, Professor McInnes has served as Director of the Arthritis Research UK Centre of Excellence for Rheumatoid Arthritis, renewed as the UK Centre for Inflammatory Arthritis through to 2024. He is Chief Investigator of the IMID-Bio-UK meta-consortium leading the UK effort to discover precision medicine tractable biomarkers for application in immune diseases. He is immediate past chairman of the FOREUM (Foundation for European Rheumatology Research) Scientific Committee, leads the European Roadmap programme that is defining the research agenda for European rheumatology for the next decade, and is President of EULAR (European Alliance of Associations for Rheumatology), the largest global transnational rheumatology organisation.

Professor McInnes is a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the recipient of several prestigious prizes in recognition of his work, including the Sir James Black Medal of the Royal Society of Edinburgh in 2017, the Heberden Medal of the British Society for Rheumatology in 2018, and the Carol-Nachman Prize for Rheumatology, Germany (the highest international award in rheumatology) in 2019. He was awarded a CBE for services to medicine by Her Majesty the Queen in 2019.

University of Dundee

Ignacio Moraga is a Principal Investigator in the Cell Signalling and Immunology Department at University of Dundee, UK. The Moraga lab studies how cytokines regulate immune cell fate decisions. The objective is to gain key insights into the molecular mechanisms that underlie cytokine functional diversity. Fundamental to the lab program is the use of protein engineering to manipulate cytokine immuno-modulatory activities with the ultimate goal to inform new therapies for immunomodulation.

Trinity College Dublin

Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. His main research interests include Toll-like receptors, Inflammasomes and Immunometabolism. Professor O’Neill is co-founder of Sitryx, which aims to develop new medicines that target immunometabolism for inflammatory diseases.


John O’Shea, MD joined the NIH in 1981, and was appointed Scientific Director of NIAMS in 2005. His interest is cytokine signaling and the role of Jaks and Stats in immunoregulation, lymphocyte differentiation, transcriptional and epigenomic regulation. His lab cloned JAK3, demonstrated its role in immunodeficiency and collaborated with industry partners in the development of therapeutic JAK inhibitors. He has received many awards, including: the Howley Prize, the Ross Prize, the Milstein Award, and the AAI-Steinward Award. He was elected to the American Association of Physicians, National Academy of Medicine and is a Master in the American College of Rheumatology.


Professor with tenure, laboratory of Human Genetics of Infectious Diseases (HGID), INSERM1163, Imagine Institute, University of Paris, Paris, France and Adjunct Faculty Member, HGID Lab, The Rockefeller University, New York City, NY, USA. Group Leader: Human genetic determinism of fungal diseases

Institute of Biochemistry and Molecular Biology II

1999-2002 IPK Gatersleben, Germany
2002-2010 Biochemical Institute, University Kiel, Germany
since 2010 Institute of Biochemistry and Molecular Biology II, University Düsseldorf, Germany

Johns Hopkins University

Dr. Jamie Spangler earned a Bachelor of Science degree in Biomedical Engineering at Johns Hopkins University and went on to earn a Ph.D. in Biological Engineering at MIT. After completing a postdoctoral fellowship at Stanford University School of Medicine, Dr. Spangler launched her independent research group at Johns Hopkins University in July 2017, jointly between the departments of Biomedical Engineering and Chemical & Biomolecular Engineering. Her lab, located in the Translational Tissue Engineering Center at the School of Medicine, applies structural and mechanistic insights to re-engineer existing proteins and design new proteins that therapeutically modulate the immune response. In particular, her group is interested in engineering immune molecules such as cytokines, growth factors, and antibodies for targeted treatment of diseases such as cancer and autoimmune disorders.

Wellcome Sanger Institute

Sarah Teichmann is interested in global principles of regulation of gene expression and protein complexes, with a focus on immunity. Sarah did her PhD at the MRC Laboratory of Molecular Biology, Cambridge, UK and was a Beit Memorial Fellow at University College London. She started her group at the MRC Laboratory of Molecular Biology in 2001, discovering stereotypical pathways of assembly and evolution of protein complexes during this time. In 2013, she moved to the Wellcome Genome Campus in Hinxton/Cambridge, jointly with the EMBL-European Bioinformatics Institute and the Wellcome Sanger Institute (WSI). In February 2016 she became Head of the Cellular Genetics Programme at the WSI and co-founded the Human Cell Atlas international initiative which she continues to lead. Sarah was elected a member of EMBO in 2012, a fellow of the Academy of Medical Sciences in 2015 and a fellow of the Royal Society in 2020.